A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease

Journal of Neurochemistry

Volumn 69, Issue 3, 1997, Pages 1326-1329

  Alam, Zafar I ^a   Daniel, Susan E ^b   Lees, Andrew J ^b   Marsden, David C ^b   Jenner, Peter ^a   Halliwell, Barry ^a,c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Incidental Lewy body disease; Oxidative damage; Parkinson's disease; Protein carbonyls

Indexed keywords

CARBONYL DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN TISSUE; LEWY BODY; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

PARKINSONIA;

EID: 0030805622     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.69031326.x     Document Type: Article

References (29)

1. Alam Z. I., Jenner A., Daniel S. E., Lees A. J., Cairns N., Marsden C. D., Jenner P., and Halliwell B. (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine in substantia nigra. J. Neurochem. 69, 1196-1203.
2. Amici A., Levine R. L., Tsai L., and Stadtman E. R. (1989) Conversion of amino acid residues in proteins and amino acid homopolymers to carbonyl derivatives by metal-catalysed oxidation reactions. J. Biol. Chem. 264, 3341-3346.
3. Beal M. F. (1997) Oxidative damage in neurodegenerative diseases. Neuroscience 3, 21-27.
4. Cross C. E., Reznick A. Z., Packer L., Davis P. A., Suzuki Y. J., and Halliwell B. (1992) Oxidative damage to human plasma proteins by ozone. Free Radic. Res. Commun. 15, 347-352.
5. Dean R. T., Fu S., Stocker R., and Davies M. J. (1997) Biochemistry and pathology of radical-mediated protein oxidation. Biochem. J. 324, 1-18.
6. Dexter D. T., Holley A. E., Flitter W. D., Slater T. F., Wells F. R., Daniel S. E., Lees A. J., Jenner P., and Marsden C. D. (1994a) Increased levels of hydroperoxides in the parkinsonian substantia nigra - an HPLC and ESR study. Mov. Disord. 9, 92-97.
7. Dexter D. T., Sian J., Rose S., Hindmarsh J. G., Mann V. M., Cooper J. M., Wells F. R., Daniel S. E., Lees A. J., Schapira A. H. V., Jenner P., and Marsden C. D. (1994b) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35, 38-44.
8. Fahn S. and Cohen G. (1992) The oxidant stress hypothesis in Parkinson's disease. Evidence supporting it. Ann. Neurol. 32, 804-812.
9. Gibb W. R. G. and Lees A. J. (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51, 745-752.
10. Halliwell B. (1996) Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Free Radic. Res. 25, 57-74.
11. Jenner P. and Olanow C. W. (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47, 161-170.
12. Levine R. L., Garland D., Oliver C. N., Amici A., Climent I., Lenz A. G., Ahn B. W., Shaltiel S., and Stadtman E. R. (1990) Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 186, 464-487.
13. Levine R. L., Williams J. A., Stadtman E. R., and Shacter E. (1994) Carbonyl assay for determination of oxidatively modified proteins. Methods Enzymol. 233, 346-357.
14. Lyras L., Evans P. J., Shaw P. J., Ince P. G., and Halliwell B. (1996) Oxidative damage and motor neurone disease. Difficulties in the measurement of protein carbonyls in human brain tissue. Free Radic. Res. 24, 397-406.
15. Lyras L., Cairns N. J., Jenner A., Jenner P., and Halliwell B. (1997) An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J. Neurochem. 68, 2061-2069.
16. Oliver C. N., Starke-Reed P. E., Stadtman E. R., Liu G. J., Carney J. M., and Floyd R. A. (1990) Oxidative damage to brain proteins, loss of glutamine synthetase activity and production of free radicals during ischaemia/reperfusion-induced injury to gerbil brain. Proc. Natl. Acad. Sci. USA 87, 5144-5147.
17. Perry T. L. and Young V. W. (1986) Idiopathic Parkinson's disease, progressive supra-nuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67, 269-274.
18. Reznick A. Z. and Packer L. (1994) Oxidative damage to protein: spectrophotometric method for carbonyl assay. Methods Enzymol. 223, 357-363.
19. Riederer P., Sofic E., Rausch W.-D., Schmidt B., Reynolds G. P., Jellinger K., and Youdim M. B. H. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
20. Saggu H., Cooksey J., Dexter D., Wells F. R., Lees A., Jenner P., and Marsden C. D. (1989) A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53, 692-697.
21. Sanchez-Ramos J. R., Overvik E., and Ames B. N. (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3, 197-204.
22. Schapira A. H. V., Cooper J. M., Dexter D., Clark J. B., Jenner P., and Marsden C. D. (1990) Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823-827.
23. Sian J., Dexter D. T., Lees A. J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., and Marsden C. D. (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36, 348-355.
24. Smith C. D., Carney J. M., Starke-Reed P. E., Oliver C. N., Stadtman E. R., Floyed R. A., and Markesbury W. R. (1991) Excess brain protein oxidation and enzyme dysfunction in normal ageing and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 88, 10540-10543.
25. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G. P., Hebenstreit G., and Youdim M. B .H. (1988) Increased iron (III) and total iron content in post-mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74, 199-205.
26. Sofic E., Lange K. W., Jellinger K., and Riederer P. (1992) Reduced and oxidised glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142, 128-130.
27. Spencer J. P. E., Jenner A., Aruoma O. I., Evans P. J., Kaur H., Dexter D. T., Jenner P., Lees A. J., Marsden D. C., and Halliwell B. (1994) Intense oxidative DNA-damage promoted by L-DOPA and its metabolites. Implications for neurodegenerative disease. FEBS Lett. 353, 246-250.
28. Spencer J. P. E., Jenner A., Butler J., Aruoma O. I., Dexter D. T., Jenner P., and Halliwell B. (1996) Evaluation of the prooxidant and antioxidant actions of L-DOPA and dopamine in vitro - implications for Parkinson's disease. Free Radic. Res. 24, 95-105.
29. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E. R., and Mizuno Y. (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc. Natl. Acad. Sci. USA 93, 2696-2701.